J&J has started its late-stage coronavirus vaccine trial

Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.

Pills 2 (2)

Hello,

Today in healthcare news: GoodRx is making its stock-market debut after pricing shares at $33 apiece just after midnight. At that price, the company is valued at $12.7 billion. What a time to be in the digital health/online prescription drug coupon business. 

Also: Johnson & Johnson has started a 60,000-person coronavirus vaccine trial, coronavirus deaths passed 200,000, and your ultimate guide to reading through vaccine data

Speaking of vaccines (and when are we not!):  Our biotech reporter Andrew Dunn is moderating a conversation on October 5 at 2 p.m. ET on the coronavirus vaccine race with 3 top experts:

  • Maria Elena Bottazzi, co-director of Texas Children's Hospital Center for Vaccine Development
  • Art Caplan, bioethicist and founding head of the Division of Medical Ethics at New York University School of Medicine
  • Dr. William Haseltine, infectious-disease expert and chair and president of ACCESS Health International

Sign up here to attend!


vaccine

Pharma giant J&J just launched a pivotal 60,000-person coronavirus vaccine trial, and we could learn if the shot works by the end of 2020

Read the full story from Andrew Dunn here>>


Coronavirus
Medical personnel move a deceased patient to a refrigerated truck serving as make shift morgues at Brooklyn Hospital Center on April 09, 2020 in New York City. -

The coronavirus has killed at least 200,000 people in the United States, another grim milestone for the pandemic

Read the full story from Yelena Dzhanova here>>


Trump NIH NIAID coronavirus vaccine
Deputy Director at the Vaccine Research Center at the National Institutes of Health, Dr. Barney Graham, speaks with President Donald Trump during a tour of the Viral Pathogenesis Laboratory at the National Institutes of Health, Tuesday, March 3, 2020, in Bethesda, Md.

5 experts lay out how they'll determine whether a coronavirus vaccine is really safe and effective — here's what to know to evaluate the data for yourself

Read the full story from Andrew Dunn here>> 


More stories we're reading:


Be sure to sign up for our newsletter here if you haven't already!

- Lydia

Read the original article on Business Insider


from Business Insider https://ift.tt/2ZWTyjd

No comments

Powered by Blogger.